Novartis AG ADR (NVS)vsRoivant Sciences Ltd (ROIV)
NVS
Novartis AG ADR
$161.93
+0.38%
HEALTHCARE · Cap: $303.67B
ROIV
Roivant Sciences Ltd
$38.88
+6.17%
HEALTHCARE · Cap: $26.81B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 761504% more annual revenue ($57.36B vs $7.53M). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
ROIV
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.93
$66.37 premium
Intrinsic value data unavailable for ROIV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% margin — thin
Weak financial health signals
ROE of -6.3% — below average capital efficiency
Revenue declined 33.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : ROIV
The strongest argument for ROIV centers on Debt/Equity, Altman Z-Score.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : ROIV
The primary concerns for ROIV are Profit Margin, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ROIV carries more volatility with a beta of 1.10 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 21/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Roivant Sciences Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive business model that leverages cutting-edge technologies. The company has developed a promising pipeline addressing critical unmet medical needs in neurology, immunology, and rare diseases, which positions it well to streamline the drug development process while managing costs effectively. With a leadership team rich in industry experience and a network of strategic partnerships, Roivant is poised to drive financial growth and improve patient outcomes, making it an attractive investment opportunity for institutional investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?